Tempus AI, Inc. (NASDAQ:TEM) stock is trading lower on Wednesday, even after Cantor Fitzgerald initiated coverage with an Overweight rating and set a price target of $80.
Analyst Sarah James says the market undervalues Tempus’ Data & Applications business by treating it as a life sciences data vendor, despite growth and margins more comparable to a platform business.
The analyst writes that, like DDOG and SNOW, Tempus sells data and AI tools to 19 of the 20 largest pharmaceutical companies and more than 250 biotechs across their R&D pipelines. This allows TEM to benefit from overall biopharma activity rather than relying on any individual drug or trial.
Tempus also follows a “one-cart” model with providers, with a single relationship spanning hereditary risk testing, CGP therapy selection, MRD monitoring and rare-disease sequencing across more than 100 assays, despite their differing clinical applications, adds the analyst.
Strong Revenue Growth Prospects
The analyst says that Tempus’ growth could be driven by five underappreciated catalysts, potentially supporting revenue above the $2.4 billion 2028 estimate versus $1.3 billion in 2025.
CGP volumes could nearly double as physician adoption expands beyond 40%-50%, while xT CDx migration and xF reimbursement could lift therapy-selection ASPs more than 40%, from about $1,850 to over $2,600, adds the analyst.
MRD, a roughly $20 billion opportunity, and the hereditary-testing gap offer additional growth avenues, with MRD volumes already up 38% quarter over quarter in the second quarter, adds the analyst.
Management estimates algorithmic diagnostics could create 50-100x their cost in value, representing another potential upside opportunity that the market may be underappreciating.
TEM Stock Price Activity: Tempus AI shares were down 2.18% at $60.91 on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
